News

Paul Rennert, president and chief scientific officer of Aleta BioTherapeutics, discussed the company’s CAR T Engager protein technology.

Six of 7 mice treated with a new, higher dose of BMN-307 showed tumors in liver necropsy at 52 weeks post-treatment.

NeuExcell and Spark Therapeutics each add to their gene therapy pipelines with the collaborative program.

The hematologist/oncologist at the Harold C. Simmons Comprehensive Cancer Center discussed the rationale behind using CAR T-cell therapy in relapsed/refractory multiple myeloma and data from the KarMMa trial.

A new animal model will facilitate the study and development of gene therapies in retinal diseases.

Experts discussed novel options such as CAR T-cell therapy for optimizing treatment in MCL, myelofibrosis, and ALL.

Experts discussed safety and efficacy data of cilta-cel for R/R MM from the CARTITUDE-1 and CARTITUDE-2 studies.

Eric Crombez, PhD, senior vice president and chief medical officer of Ultragenyx Gene Therapy, discussed indications the company is targeting.

Magali Taiel, MD, chief medical officer, GenSight Biologics, discussed future research the company plans to pursue.

The FDA has cleared a batch of VB-111 manufactured in Modiin, Israel, following a technical review.

Experts discuss emerging agents in the pipeline for the treatment of RRMM; including BCMA-targeted bispecific antibodies.

With numerous targets in CNS diseases and a unique partnership with gene therapy experts at UT Southwestern, Taysha is hoping to fill significant unmet needs.

A post-hoc analysis overviewed long-term efficacy of autologous hematopoietic stem cell transplantation in mantle cell lymphoma.

The hematologist from UC Health discussed the role of allogeneic stem cell transplant at first remission based on risk stratification.

The early-phase data readout follows news that the FDA recently approved its IND for its CAR-T candidate in multiple myeloma.

Experts discussed treatment for patients with transplant-ineligible diffuse large B-cell lymphoma.

The first US-based patient has been dosed in Lysogene’s clinical trial of LYS-GM101, following 2 other competing trials.

The associate professor from The University of Texas MD Anderson Cancer Center discussed future research with CAR T therapy in multiple myeloma.

Patients with MDS treated with alloHSCT and 5-aza had significant improvements in event-free survival compared to 5-aza treatment alone.

Experts discussed data from trials in lymphoma presented at ASCO 2021.

An international panel of experts discussed needs and challenges in the field.

The chief of Oncology and Hematology at University of Nebraska Medical Center, discussed the potential utility of CAR T-cell therapy across the non-Hodgkin lymphoma (NHL) paradigm.

The 4-day virtual conference will feature plenary presentations, workshops, and bootcamps led by cell therapy industry leaders with expertise in discovery, development, manufacturing, and more.

Both Vertex and Arbor are adding to their list of gene and cell therapy partnerships with the announcement.

The chief executive and chief medical officers of Celyad Oncology discussed their platform and positive data presented at EHA 2021.

The 2 companies will focus their strategic partnership on the development of gene therapies for rare diseases, as well.

Mariya Moosajee, MBBS, BSc, PhD, FRCOphth, discussed the next generation of gene therapy for inherited retinal diseases.